Affiliation:
1. University of Rochester, NY, Department of Psychiatry, 300 Crittenden Blvd, Rochester,
NY 14642, USA,
Abstract
Clozapine is known as the first `atypical' medication and is effective in people who have treatment-resistant schizophrenia. Its 1990 emergence in the USA was marked by considerable controversy over its high cost, due in large part to having been both the first new antipsychotic medication to come to market in over a decade and the need for comprehensive safety monitor ing within a decentralized health system. This paper traces the histor y of clozapine's discover y and development in Europe, its part in the 1975 Finnish agranulocytosis scare, and its subsequent volatile emergence in the USA. Analyses examine peripheral forces at the time, particularly the influence of political, corporate, medical and societal forces which shaped its market course.
Subject
Psychiatry and Mental health
Reference54 articles.
1. Adams, M.E., Chang, H. and Frazier, H.S. (1995) Clozapine therapy for schizophrenia. In J. D. Graham and J. B. Wienert (eds), Risk vs. Risk: Tradeoffs in Protecting Health and the Environment (Cambridge, MA: Harvard University Press), 53—71.
2. Agranulocytosis in patients treated with clozapine.
3. Clozapine-induced agranulocytosis: A situation report up to August 1976
Cited by
198 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献